Controversy still surrounds muscular dystrophy drug
Cost of Iclusig jumped four times this year
U.S. hospitals borrow idea from South Africa
Monoclonal antibody bests chemotherapy
ALKS 5461 is effective as adjunctive therapy
Chlamydia, gonorrhea, and syphilis take double-digit jumps
First new initial treatment of STS in more than 40 years
Desmopressin nasal spray gets ‘thumbs up,’ with reservations
Device bypasses expensive ‘clean rooms’

P&T October 2016
Table of Contents


More than a decade of war in the Middle East has pushed post-traumatic stress disorder (PTSD) to the forefront of public health concerns. The author defines the disorder and discusses risk factors, treatments, and the barriers to effective care.
Rising acquisition costs for sodium nitroprusside, indicated for the treatment of perioperative hypertension in cardiac surgery, prompt a medical center to implement a cost-effective alternative that will result in savings of about $300,000 in 2016.
The authors present their findings after conducting a literature review of peer-reviewed articles evaluating the use of dexmedetomidine for the treatment of delirium to support the off-label use of the drug in the intensive care unit.
Meeting Highlights
More than 33,000 cardiologists and allied medical professionals gathered in Rome to share the latest cardiac research. We review key sessions from a wide range of therapeutic areas, including anticoagulation, obesity, and hypercholesterolemia.
Pipeline Plus
Patients with type-2 diabetes can control their blood glucose levels through diet and exercise, by losing excess weight, and by taking medications, such as first-line metformin. We examine several promising drugs in the type-2 diabetes pipeline.


Medication Errors
Risk-reduction strategies for high-alert medication lists
Prescription: Washington
Generic companies press for REMS relief with Senate bill
Approvals, new indications, regulatory activities, and more
Obeticholic acid (Ocaliva) for primary biliary cholangitis; sofosbuvir 400 mg/velpatasvir 100 mg (Epclusa) for chronic hepatitis C virus infection; and daclizumab (Zinbryta) for relapsing multiple sclerosis
Drug Forecast
Mepolizumab (Nucala) for severe eosinophilic asthma


The Role of T-VEC and Other Intralesional Agents

Robert H. I. Andtbacka, MD, of the Huntsman Cancer Institute in Utah, discusses the place in therapy of talimogene laherparepvec (T-VEC) and other intralesional oncolytic agents for melanoma patients, both as monotherapy and in combination with treatments including checkpoint inhibitors.

American Society of Clinical Oncology, June 2016